Dossier assessment
Abemaciclib (breast cancer) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Abemaciclib (breast cancer) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Abemaciclib (breast cancer) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adjuvant treatment of patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
- Premenopausal women: hint of minor added benefit
- Postmenopausal women: added benefit not proven
- Men: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2022-10-20 A G-BA decision was published.
Project details
- Project no.
- A22-51
- Commission
- Commission awarded on 29.04.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2022-10-10.
Connected Projects
-
Dossier assessment
Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Abemaciclib in combination with an aromatase inhibitor (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Abemaciclib in combination with fulvestrant (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Abemaciclib (breast cancer; adjuvant treatment) - Addendum to Commission A22-51
Status: Commission completed
-
Dossier assessment
Abemaciclib (breast cancer; combination with an aromatase inhibitor) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Abemaciclib (breast cancer; adjuvant treatment) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed